1 - 10 of 20 articles
Although numerous studies have reported that a positive surgical margin
(PSM) is the most important predictive factor for biochemical recurrence (BCR)
of prostate cancer (PCa), only a small number of studies have evaluated the predictive
value of the Gleason...
Malignant pleural mesothelioma (MPM) is considered a relatively uncommon
disease but its incidence is increasing worldwide. Patients affected by MPM have
a very severe prognosis and have been often occupationally and environmentally
exposed to asbestos. In...
Although progress has been made in the early diagnosis of colorectal cancer
(CRC) and in the systemic therapy of patients with CRC, the prognosis for advanced
CRC remains poor. Our previous study demonstrated that ARHGAP25 overexpression
It is well known that cancer cells produce energy via anaerobic glycolysis.
Lipid metabolism is often upregulated in numerous types of cancer. Our previous
study demonstrated that adipophilin (ADP), a lipid‑associated protein, was a poor
prognostic indicator in...
Low‑grade endometrial stromal sarcoma (LGESS) is a rare uterine tumor, accounting
for <1% of all uterine cancer cases. LGESS has several variations and the
frequency of tumors exhibiting smooth muscle differentiation is 10‑30% of LGESS
cases, making such...
Mammary microcalcifications (MCs) are calcium deposits that are considered
as robust markers of breast cancer when identified on mammography. MCs are frequently
associated with premalignant and malignant lesions. The aim of the present review
was to describe...
Cancer is a major health issue worldwide. cfDNA integrity has been reported
as a potential diagnostic molecular marker for different types of cancer, identifying
the importance of liquid biopsy. The aim of this review was to evaluate the prognostic
The effect of BMI as a risk factor in trastuzumab-induced cardiotoxicity
in Saudi patients with HER2‑neu positive breast cancer treated with trastuzumab
and anthracyclines is not fully understood. The present study retrospectively
evaluated the overall...
NTRK gene fusion is rare in gynecological cancer. Entrectinib
is a novel targeted drug, which is a potent inhibitor of TRK A, B and C. The present
case report described a case of recurrent ovarian cancer with TPM3‑NTRK1
patient plasma or tissue samples have been implemented to date. The present
study was designed to assess the ability of different technologies to detect the
T790M mutation in plasma samples and to evaluate the relative rates of re‑biopsy
and subsequent patient...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.